FN3K and hepatocellular carcinoma: NSMIs targeting vulnerable FN3K could be an effective strategy to maintain Nrf2 in an inactive state; this was concluded from a genomic study in FN3K knockout mice models, where the data supported a specific need of FN3K for oncogenic Nrf2-driven lung and liver carcinomas [87,151].